Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab beta plus chemotherapy for refractory or relapsed/progressive neuroblastoma
2024-513141-37-00Phase 3Completed
- Sponsor
- Jagiellonian University Medical College
- Start
- May 2024
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of Dinutuximab beta in neuroblastoma, sponsored by Jagiellonian University Medical College. Primary endpoints: Number of cycles aborted due to toxicity, Number of cycles with prolonged treatment interruption due to adverse effects and 8 more. Started May 2024; status: completed.
02
Drugs
Dinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2024-513141-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513141-37-00.